Investigation of Cytotoxic Effects of Recombinant Human Interferon Lambda-1 and Its Pegylated Form on Human Conjunctival Epithelial Cells

Currently, there are no efficacious, all-purpose antiviral medicines for the treatment of ocular surface infections caused by viruses. At the same time, type III interferons demonstrate high potency for histological barriers, such as the conjunctiva. Modification of protein molecules in native products can significantly improve their pharmacodynamic properties. Thus, it seems reasonable to develop antiviral medicines based on interferon lambda (IFN-λ1) and its pegylated form (PEG IFN-λ1).

The aim of the study was to evaluate the in vitro cytotoxic effect of recombinant human IFN-λ1 and its pegylated form on Chang conjunctiva clone 1-5c-4 human conjunctival cells.

Materials and methods: PEG IFN-λ1 was obtained by the electron beam immobilisation method. A normal human conjunctival cell line Chang conjunctiva clone 1-5c-4 was used for cell cultivation. The MTT test was used to assess the cytotoxic effect. Cell proliferative activity was studied by measuring microelectrode impedance. Ultrastructural changes were assessed by electron microscopy. Statistical processing was performed using the Statistica 10.0 software package.

Results: IFN-λ1 (37 μg/mL) and PEG IFN-λ1 (42 μg/mL) had no significant cytotoxic effect on the human conjunctiva cell culture and the cell proliferative activity. The analysis of ultrastructural changes demonstrated that IFN-λ1 activated metabolic processes in the cells, and PEG IFN-λ1 promoted differentiation and keratinisation of epithelial cells and led to modification of the cell membrane. A ten-fold increase in IFN-λ1 and PEG IFN-λ1 concentration (to 370 μg/mL and 420 μg/mL, respectively) reduced the cell viability by 15–20% as compared to the intact control.

Conclusions: the study results demonstrated that IFN-λ1 and PEG IFN-λ1 could be used as active pharmaceutical ingredients in the development of medicines for the treatment of conjunctival viral infections.

1. Soares S, Sousa J, Pais A, Vitorino C. Nanomedicine: principles, properties, and regulatory issues. Front Chem. 2018;6:360. https://doi.org/10.3389/fchem.2018.00360

2. Madonov PG, Kikhtenko NA, Oleynik LA, Udut VV. Interferon lambda — the new representative of pharmacologically active interferons. Eksperimental’naya i klinicheskaya farmakologiya = Experimental and Clinical Pharmacology. 2020;83(6):30–7 (In Russ.) https://doi.org/10.30906/0869-2092-2020-83-6-30-37

3. Lazear HM, Nice TJ, Diamond MS. Interferon-λ: immune functions at barrier surfaces and beyond. Immunity. 2015;43(1):15–28. https://doi.org/10.1016/j.immuni.2015.07.001

4. Ye L, Schnepf D, Staeheli P. Interferon-λ orchestrates innate and adaptive mucosal immune responses. Nat Rev Immunol. 2019;19(10):614–25. https://doi.org/10.1038/s41577-019-0182-z

5. Antony F, Pundkar C, Sandey M, Jaiswal AK, Mishra A, Kumar A, et al. IFN-λ regulates neutrophil biology to suppress inflammation in herpes simplex virus-1-induced corneal immunopathology. J Immunol. 2021;206(8):1866–77. https://doi.org/10.4049/jimmunol.2000979

6. Feroze KB, Wang J. Interferon Induced Retinopathy. StatPearls; 2020. PMID: 28722892

7. Rentiya ZS, Wells M, Bae J, Chen KJ, Chao AN, Turgeon N, et al. Interferon-α-induced retinopathy in chronic hepatitis C treatment: summary, considerations, and recommendations. Graefes Arch Clin Exp Ophthalmol. 2019;257(3):447–52. https://doi.org/10.1007/s00417-018-04209-7

8. Medhat E, Esmat G, Hamza E, Abdel AA, Fouad FW, Darweesh SK, et al. Ophthalmological side effects of interferon therapy of chronic hepatitis C. Hepatobiliary Surg Nutr. 2016;5(3):209–16. https://doi.org/10.21037/hbsn.2015.12.14

9. Bekarev AA, Artamonov AV, Vereshchagin EI. Method for immobilizing a biologically active substance (BAS) on a carrier (variants) and a BAS-carrier conjugate obtained by these methods. Patent of the Russian Federation No. 24009669; 2008 (In Russ.)

10. Wylie DC, Voloch M, Lee S, Liu YH, Cannon-Carlson S, Cutler C, Pramanik B. Carboxyalkylated histidine is a pH-dependent product of pegylation with SC-PEG. Pharm Res. 2001;18(9):1354–60. https://doi.org/10.1023/a:1013006515587

11. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12(2):195–202. https://doi.org/10.1021/bc000082g

12. Mishenina SV, Madonov PG, Baykalov GI, Leontyev SG, Zotov SP. The oral thrombolysis for venous thrombosis (clinical study). Tromboz, gemostaz i reologiya = Thrombosis, Hemostasis and Rheology. 2019;(4):54–67 (In Russ.) https://doi.org/10.25555/THR.2019.4.0900

13. Artamonov AV, Bekarev AA, Dygay AM, Zhdanov VV, Kinsht DN, Madonov PG, Sherstoboev EYu. Pegylated interferon lambda with high oral bioavailability and method for its production. Patent of the Russian Federation No. 2678332 C1; 2017 (In Russ.)

14. Kikhtenko NA, Ilyicheva TN, Durymanov AG, Fursova AZh, Madonov PG. Investigation of the antiviral activity of the recombinant human interferon lambda 1 in human conjunctiva cell culture. Sibirskiy nauchny meditsinskiy zhurnal = Siberian Scientific Medical Journal. 2021;41(5):31–6 (In Russ.) https://doi.org/10.18699/SSMJ20210504

15. Tovey MG, Lallemand C. Safety, tolerability, and immunogenicity of interferons. Pharmaceuticals (Basel). 2010;3(4):1162–86. https://doi.org/10.3390/ph3041162

16. Nesterova IV. Interferon alfa in clinical practice. Rossiyskiy allergologicheskiy zhurnal = Russian Journal of Allergy. 2010;(2):43–52 (In Russ.)